Published online Feb 14, 2023. doi: 10.3748/wjg.v29.i6.1076
Peer-review started: October 14, 2022
First decision: December 1, 2022
Revised: December 13, 2022
Accepted: January 29, 2023
Article in press: January 29, 2023
Published online: February 14, 2023
Processing time: 119 Days and 7.1 Hours
Esophagogastric variceal bleeding (EGVB) is a fatal complication of liver cirrhosis, which requires aggressive intervention. Prediction of bleeding risk in cirrhotic patients with esophagogastric varices (EGV) is beneficial to individualized treatment and improve prognosis. Radiomics, an emerging field, has a good performance in disease diagnosis and efficacy evaluation.
Currently, there is still a lack of noninvasive models that can be widely used in clinical practice to predict the risk of bleeding in liver cirrhosis.
Our study aimed to develop and validate a novel predictive model based on radiomics extracted from contrast-enhanced computed tomography (CT) and clinical indicators to noninvasively assess the risk of bleeding in cirrhotic patients with EGV.
211 patients were divided into training and validation cohorts in a 7:3 ratio. Radiomics features were extracted from the portal venous phase CT images, and a radiomics signature (RadScore) was constructed through further feature dimension reduction and screening. The univariate and multivariate logistic regression analyses were preformed to select independent clinical predictors. Finally, a combined model was established based on RadScore and clinical variables. The receiver operating characteristic curves, calibration curves, clinical decision curves and clinical impact curves were applied to evaluate the performance of the model.
The RadScore was constructed from 8 radiomics features. Albumin, fibrinogen, portal vein thrombosis, aspartate aminotransferase, and spleen thickness were selected as independent predictors. The nomogram, combining RadScore and clinical variables, demonstrated good diagnostic performance in both the training and validation cohorts (area under the receiver operating characteristic curve (AUC) = 0.925 and 0.912, respectively), which outperformed existing non-invasive models such as ratio of aspartate aminotransferase to platelets and Fibrosis-4 scores (Delong test < 0.05).
The combined model based on radiomics features and clinical indicators shows good predictive accuracy and can contribute to noninvasively assessing the risk of EGVB in patients with cirrhosis.
Radiomics has shown good diagnostic performance in the assessment of portal hypertension and the identification of high-risk esophageal varices. Our study demonstrated that the model combined clinical variables and radiomics features has the potential utility for non-invasive prediction of EGVB. Further large-scale, multi-center prospective studies are still required to verify its performance in the future.